Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has provided an announcement.
Proteomics International Laboratories Ltd has successfully secured A$4.5 million through a placement to institutional and sophisticated investors to support the commercial launch of its Promarker diagnostic tests in the US and Australia. The funds will be used to launch PromarkerD, PromarkerEso, and PromarkerEndo tests, upgrade systems for clinical diagnostics in Australia, and establish laboratory platforms in the USA, enhancing the company’s market positioning in precision diagnostics.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on the development and commercialization of diagnostic tests. The company is known for its Promarker suite of diagnostic tests, which includes PromarkerD for predicting diabetic kidney disease, PromarkerEso for diagnosing esophageal cancer, and PromarkerEndo for diagnosing endometriosis.
YTD Price Performance: -44.38%
Average Trading Volume: 130,702
Technical Sentiment Signal: Buy
Current Market Cap: A$58.3M
See more data about PIQ stock on TipRanks’ Stock Analysis page.